Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;28(2):168-75.
doi: 10.1097/BOR.0000000000000250.

Biomarkers to guide clinical therapeutics in rheumatology?

William H Robinson  1 , Rong Mao
Affiliations
Review

Biomarkers to guide clinical therapeutics in rheumatology?

William H Robinson et al. Curr Opin Rheumatol. 2016 Mar.

Abstract

Purpose of review: The use of biomarkers in rheumatology can help identify disease risk, improve diagnosis and prognosis, target therapy, assess response to treatment, and further our understanding of the underlying pathogenesis of disease. Here, we discuss the recent advances in biomarkers for rheumatic disorders, existing impediments to progress in this field, and the potential of biomarkers to enable precision medicine and thereby transform rheumatology.

Recent findings: Although significant challenges remain, progress continues to be made in biomarker discovery and development for rheumatic diseases. The use of next-generation technologies, including large-scale sequencing, proteomic technologies, metabolomic technologies, mass cytometry, and other single-cell analysis and multianalyte analysis technologies, has yielded a slew of new candidate biomarkers. Nevertheless, these biomarkers still require rigorous validation and have yet to make their way into clinical practice and therapeutic development. This review focuses on advances in the biomarker field in the last 12 months as well as the challenges that remain.

Summary: Better biomarkers, ideally mechanistic ones, are needed to guide clinical decision making in rheumatology. Although the use of next-generation techniques for biomarker discovery is making headway, it is imperative that the roadblocks in our search for new biomarkers are overcome to enable identification of biomarkers with greater diagnostic and predictive utility. Identification of biomarkers with robust diagnostic and predictive utility would enable precision medicine in rheumatology.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Applications of biomarkers at different stages in the development of rheumatic diseases.
See this image and copyright information in PMC

References

    1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual, framework. Clin Pharmacol Ther. 2001;69:89–95. - PubMed
    1. Nair N, Mei HE, Chen SY, et al. Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy. Arthritis Res Ther. 2015;17:127. [The article reviewed mass cytometry-based approaches to identify novel cellular biomarkers for rheumatic diseases.] - PMC - PubMed
    1. O'Gorman WE, Hsieh EW, Savig ES, et al. Single-cell systems-level analysis of human toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus. J Allergy Clin Immunol. 2015;136:1326–1336. - PMC - PubMed
    1. Castro-Santos P, Laborde CM, Diaz-Pena R. Genomics, proteomics and metabolomics: their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers. Clin Exp Rheumatol. 2015;33:279–286. - PubMed
    1. Eckstein F, Collins JE, Nevitt MC, et al. Cartilage thickness change as an imaging biomarker of knee osteoarthritis progression: data from the fnih OA biomarkers consortium. Arthritis Rheumatol. 2015 - PMC - PubMed

Publication types